
<DOC>
<DOCNO>WT02-B19-5</DOCNO>
<DOCOLDNO>IA092-000988-B014-336</DOCOLDNO>
<DOCHDR>
http://www.cytrx.com:80/prmax.htm 206.216.36.35 19970110093834 text/html 2613
HTTP/1.0 200 OK
Date: Friday, 10-Jan-97 09:41:22 GMT
Server: WebSite/1.1
Allow-ranges: bytes
Accept-ranges: bytes
Content-type: text/html
Last-modified: Friday, 03-Jan-97 17:16:02 GMT
Content-length: 2398
</DOCHDR>
<HTML>

<HEAD>

<TITLE>Dr. Max Link Joins CytRx Board of Directors </TITLE>


</HEAD>

<BODY background=/icons/wrich/bg.gif>

<table width=95%><tr>
<td align=left>	
	<img src=/icons/cytrx.48pt.gif>
	</td>
<td align=right>
	<img src=/icons/multiopp.gif>
	</td>
</tr></table>
<img src=/icons/wrich/redline.gif>

<P>

<P>
<B><FONT SIZE=4>Dr. Max Link Joins CytRx Board of
Directors <BR>
</FONT></B>
<P>
<B>Atlanta, Georgia, November 11, 1996<BR>
</B>
<P>
CytRx Corporation (NASDAQ:CYTR) today announced
it has appointed Max Link, Ph.D., to its Board of Directors. 
Dr. Link is an internationally recognized pharmaceutical expert.
 His extensive pharmaceutical industry experience includes serving
as the Chief Executive Officer of Corange -- the holding company
for the Boehringer Mannheim Therapeutics, Boehringer Mannheim
Diagnostics and DePuy International.  Dr. Link is the former Chairman
of Sandoz Pharma.  

<P>
“Dr. Link is an excellent addition to
our Board,” commented Jack J. Luchese, CytRx president and
Chief Executive Officer.  “He brings a wealth of pharmaceutical
development experience to CytRx.  We look forward to benefiting
from his guidance and counsel.” 

<P>
In addition to CytRx, Dr. Link currently serves
on the Boards of Directors of Protein Design Laboratories, Alexion
Pharmaceuticals, Human Genom Sciences and Procept.  

<P>
CytRx Corporation's business strategy
is to build shareholder value through the development and commercialization
of high value human therapeutic products, while capitalizing on
other biopharmaceutical opportunities through its unique subsidiary
structure.  CytRx's is developing RheothRx<SUB>pf</SUB>
to treat vascular occlusive diseases including acute sickle cell
crisis.  CytRx's Vaxcel subsidiary is developing Optivax&#174;
to improve the effectiveness of vaccines.  Vetlife markets and
distributes products to enhance food animal growth.  Proceutics
provides high quality preclinical development services to the
pharmaceutical industry. 
<BR>
<P>


<img src="/icons/rain_line.gif">	
<p>
<b>
[ <a href="/index.html">Home</a> 
| <a href="http://www.titermax.com">TiterMax</a> 
| <a href="/financial/overview.html">Investor Info</a> 
| <a href="/communications.html">Communications</a> 
| <a href="/adproceu.html">Proceutics</a>  
] </b>
<p>
</BODY>

</HTML>

</DOC>